title: [Calcineurin-inhibitor-free immunosuppression in early renal transplantation].
abstract: Calcineurin inhibitors are one of the most common drugs used for prevention of acute rejection in recipients of renal allografts. New immunosuppressors have reduced the incidence of acute renal allograft rejection. There have been numerous recent attempts to develop alternative patterns of immunosuppressors for prevention of chronic renal allograft failure, and enhancing its survival. We described a patient who developed numerous complications after the initial postransplant period. He was treated with a calcineurin inhibitors-free immunosuppression in order to avoid nephrotoxicity, but had over 30 ng/ml of sirolimus. Renal function was impaired after cyclosponne withdrawal. Sirolimus was used in association with mycofenolate mofetil and prednisone.
authors.affiliation: Servicio de Nefrología, Hospital Universitario La Paz, Madrid. tolea@uoc.edu
authors.forename: T
authors.initials: T
authors.lastname: Olea
authors.forename: C
authors.initials: C
authors.lastname: Jiménez
authors.forename: F
authors.initials: F
authors.lastname: Escuín
authors.forename: A
authors.initials: A
authors.lastname: García de Miguel
authors.forename: S
authors.initials: S
authors.lastname: Ros
authors.forename: A
authors.initials: A
authors.lastname: Sanz
mesh_terms: D000328:Adult; D065095:Calcineurin Inhibitors; D015897:Comorbidity; D016572:Cyclosporine / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005334:Fever / Q000209:etiology; D005923:Glomerulosclerosis, Focal Segmental / Q000150:complications / Q000601:surgery; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000139:chemically induced; D016030:Kidney Transplantation; D008297:Male; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D011704:Pyelonephritis / Q000209:etiology; D012008:Recurrence; D020123:Sirolimus / Q000008:administration & dosage / Q000627:therapeutic use; D014515:Ureteral Diseases / Q000209:etiology; D001747:Urinary Bladder Fistula / Q000209:etiology; D014548:Urinary Fistula / Q000209:etiology
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid; D011241:Prednisone; D020123:Sirolimus